Could a simple Anti-Inflammatory drug save lives after aortic tear?

NCT ID NCT06968806

Recruiting now Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether the anti-inflammatory drug ketorolac can improve outcomes in 360 people undergoing emergency surgery for a life-threatening aortic dissection. Participants receive either ketorolac or a placebo before and after surgery, alongside standard care. Researchers will track complications, organ function, and survival for up to 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ketorolac (an anti-inflammatory painkiller)
What this could lead to: If it works, this could point toward a simple, low-cost way to reduce serious complications and improve survival after emergency aortic dissection surgery.
What could go wrong: This is a single-center trial with 360 patients, so results may not apply broadly. Ketorolac can increase bleeding risk, which is especially concerning in this surgical setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC DISSECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aortic Dissection Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC DISSECTION INFLAMMATION

Contacts and locations

Locations

Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.